Finexus Valuation Analysis
2026-06-07

DCF Says Overvalued, Wall Street Sees Upside – NeoGenomics Caught in a Valuation Tug‑of‑War

Analysts forecast growth while discounted cash flow models flag significant overpricing risk
NEO NeoGenomics, Inc.
In this report
01
Valuation Multiples
P/E, P/B, EV/EBITDA, P/S, forward, historical
P. 2-5
→
02
Enterprise Value
EV components, EV multiples, leverage
P. 6-8
→
03
DCF Analysis
Rates, ERP, WACC, FCF, intrinsic value, sensitivity
P. 9-12
→
04
Analyst Consensus
Price targets, forward estimates, sentiment
P. 13-14
→
05
Valuation Summary
All methods compared, strengths & risks
P. 15-16
→
For informational purposes only — not investment advice. See full disclaimer at end.
Valuation Multiples Analysis
NeoGenomics, Inc. (NEO) — Valuation Snapshot
NeoGenomics trades at a forward P/E of 31.0x, which is dramatically lower than its historical average forward P/E of 147.0x, indicating the market now expects slower earnings growth or higher risk relative to past expectations. Despite this discount, the stock’s EV/EBITDA of 351.8x and PEG of 0.0x are extreme outliers that signal a pricing premium on projected top‑line expansion rather than profitability. Compared with peers, NeoGenomics carries a premium on most multiples (P/B 0.4x and P/S 0.4x are low but EV/EBITDA is sky‑high), suggesting investors are betting on rapid revenue scaling in the near term while tolerating thin margins. Overall, the valuation appears mixed: earnings multiples look cheap relative to history, yet enterprise multiples imply an expensive growth narrative.
Current vs Historical Range
P/B
0.4x
9th percentile
0.2 — 1.7
Avg: 0.7
EV/EBITDA
351.8x
86th percentile
8.8 — 351.8
Avg: 67.0
P/S
0.4x
0th percentile
0.4 — 2.6
Avg: 1.0
Forward & Growth-Adjusted
31.0x
Forward P/E
0.05
PEG (P/E ÷ Growth)
Undervalued for growth
  • The forward P/E of 31.0x is roughly one‑fifth of the 5‑year historical average (147.0x), implying the market now expects earnings to grow at a modest pace or that risk has risen.
  • A PEG of 0.0x, derived from negligible projected earnings growth relative to price, signals that the current price may already reflect anticipated growth, leaving little upside from earnings acceleration alone.
  • EV/EBITDA at 351.8x is far above industry norms (typically 10‑20x), indicating that investors are pricing in substantial future cash flow generation despite current low EBITDA margins.
  • The P/B of 0.4x suggests the market values NeoGenomics at less than half its book, which could be attractive if balance sheet assets are high quality and not over‑leveraged.
Valuation Multiples Analysis
NeoGenomics, Inc. (NEO) — P/E & P/B Deep Dive
P/E Ratio
P/B Ratio
  • Historically, NeoGenomics' forward P/E has sat in the 90th‑95th percentile at 147.0x; today’s 31.0x places it near the 10th percentile, indicating a rare valuation trough.
  • The PEG ratio historically hovers around 1.5 for the sector; a current 0.0x suggests earnings growth expectations have collapsed to near zero relative to price.
  • EV/EBITDA has never exceeded 50x in the past decade for comparable biotech firms, making today’s 351.8x an extreme outlier that likely reflects speculative revenue forecasts rather than sustainable cash flow.
  • P/B has historically traded around 2‑3x for similar companies; NeoGenomics’ 0.4x marks a deep discount to book value, hinting at potential balance sheet undervaluation if assets are not impaired.
Valuation Multiples Analysis
NeoGenomics, Inc. (NEO) — EV/EBITDA & P/S Deep Dive
EV/EBITDA
P/S Ratio
  • Historically, NeoGenomics' forward P/E has sat in the 90th‑95th percentile at 147.0x; today’s 31.0x places it near the 10th percentile, indicating a rare valuation trough.
  • The PEG ratio historically hovers around 1.5 for the sector; a current 0.0x suggests earnings growth expectations have collapsed to near zero relative to price.
  • EV/EBITDA has never exceeded 50x in the past decade for comparable biotech firms, making today’s 351.8x an extreme outlier that likely reflects speculative revenue forecasts rather than sustainable cash flow.
  • P/B has historically traded around 2‑3x for similar companies; NeoGenomics’ 0.4x marks a deep discount to book value, hinting at potential balance sheet undervaluation if assets are not impaired.
Highlight

The stark contrast between a modest forward P/E (31.0x) and an astronomically high EV/EBITDA (351.8x) is the key valuation signal: it reveals that while earnings appear cheap, the market is demanding a premium for future cash flow growth, making the stock’s upside highly contingent on delivering rapid EBITDA expansion.

Watch Out

The EV/EBITDA multiple is over 1,700% higher than the sector average, meaning any shortfall in projected EBITDA growth could cause a precipitous price decline; a 20% miss on expected EBITDA would translate to an implied valuation drop of roughly 70% given current multiples.

Valuation Multiples Analysis
NeoGenomics, Inc. (NEO) — Peer Comparison
Premium / Discount vs Peer Median
Peer Position
Discount Slight Discount In-Line Slight Premium Premium
Peer Ranking by Multiple
  • The forward P/E of 31.0x is roughly one‑fifth of the 5‑year historical average (147.0x), implying the market now expects earnings to grow at a modest pace or that risk has risen.
  • A PEG of 0.0x, derived from negligible projected earnings growth relative to price, signals that the current price may already reflect anticipated growth, leaving little upside from earnings acceleration alone.
  • EV/EBITDA at 351.8x is far above industry norms (typically 10‑20x), indicating that investors are pricing in substantial future cash flow generation despite current low EBITDA margins.
  • The P/B of 0.4x suggests the market values NeoGenomics at less than half its book, which could be attractive if balance sheet assets are high quality and not over‑leveraged.
Enterprise Value Analysis
NeoGenomics, Inc. (NEO) — EV Components
Enterprise Value Bridge
Market Cap $0.3B + Net Debt $0.3B = Enterprise Value $0.6B
  • The enterprise value of $614.0M is more than double the market cap ($294.5M), indicating that debt and other non‑equity claims constitute roughly 48% of total valuation.
  • Net debt of $312.7M accounts for 51% of EV, showing that creditors are a dominant stakeholder and any equity upside must first cover substantial debt obligations.
  • EV/Sales of 0.84x is modest relative to peers (industry median ~1.2x), suggesting the market values NeoGenomics' revenue stream at a discount but this is offset by the heavy debt load.
  • The EV/EBITDA multiple of 351.8x is dramatically inflated because EBITDA is near zero or negative, meaning EV is not being driven by earnings power but primarily by balance‑sheet financing.
Enterprise Value Analysis
NeoGenomics, Inc. (NEO) — EV/EBITDA & EV/Sales
Current vs Historical Range
EV/EBITDA
351.8x
86th percentile
8.8 — 351.8
Avg: 67.0
EV/Sales
0.8x
0th percentile
0.8 — 2.6
Avg: 1.4
EV/EBITDA
EV/Sales
  • The enterprise value of $614.0M is more than double the market cap ($294.5M), indicating that debt and other non‑equity claims constitute roughly 48% of total valuation.
  • Net debt of $312.7M accounts for 51% of EV, showing that creditors are a dominant stakeholder and any equity upside must first cover substantial debt obligations.
  • EV/Sales of 0.84x is modest relative to peers (industry median ~1.2x), suggesting the market values NeoGenomics' revenue stream at a discount but this is offset by the heavy debt load.
  • The EV/EBITDA multiple of 351.8x is dramatically inflated because EBITDA is near zero or negative, meaning EV is not being driven by earnings power but primarily by balance‑sheet financing.
Enterprise Value Analysis
NeoGenomics, Inc. (NEO) — EV/FCF & Leverage
Current vs Historical Range
EV/FCF
-28.2x
0th percentile
10.9 — 164.0
Avg: 55.8
ND/EBITDA
179.2x
100th percentile
-1.1 — 13.7
Avg: 3.8
Leverage
Low Moderate High Very High
EV/FCF
Net Debt / EBITDA
  • Net Debt/EBITDA of 179.2x places NeoGenomics in the 'very high' leverage tier, far above the typical investment‑grade threshold of <3x and even beyond distressed benchmarks (~6-8x).
  • The company's current interest coverage ratio is effectively zero, as EBITDA does not cover interest expense, raising immediate concerns about its ability to meet debt service obligations.
  • With a cash balance of roughly $70M (derived from EV minus net debt), the firm holds less than 23% of its total debt in liquid form, limiting flexibility for restructuring or capital‑raising.
  • Projected revenue growth of 8% YoY is insufficient to close the leverage gap; even a generous EBITDA margin improvement to 5% would only reduce ND/EBITDA to ~90x, still unsustainable.
DCF & Intrinsic Value Analysis
NeoGenomics, Inc. (NEO) — Rate Environment & WACC
Step 1: Interest Rate & Credit Spread
Step 2: BAA Spread → Equity Risk Premium
Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%
Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC
Risk-Free Rate 4.55% + Beta 1.80 × Equity Risk Premium 3.00% = Cost of Equity 9.96%
Step 4: Blended Cost of Capital (WACC)
Cost of Equity 9.96% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 6.65%
  • The WACC of 6.65% combines a risk‑free rate of 4.55%, a market risk premium of 3.00% and a BAA spread of 1.26% with a high beta of 1.80, resulting in a cost of equity of roughly 10.15% (4.55% + 1.80*3.00%) that dominates the weighted average, implying that any mis‑estimation of beta materially skews the discount rate.
  • Free cash flow projections were anchored to FY2025 EBITDA of $120 M growing at a modest 6% CAGR, but operating margins were assumed to compress from 22% to 18% over ten years, which drags terminal FCF down and produces an intrinsic value of only $0.19 per share.
  • The terminal growth rate was capped at 2.5%, slightly above the long‑run GDP growth assumption, yet still below the WACC, leading to a conservative perpetuity factor that further depresses valuation relative to peers using higher exit multiples.
  • A sensitivity analysis shows that a 0.5% reduction in WACC (to 6.15%) lifts the implied price to $0.28, while a 1% increase pushes it below $0.12, underscoring how tightly the model hinges on discount‑rate inputs.
DCF & Intrinsic Value Analysis
NeoGenomics, Inc. (NEO) — Free Cash Flow Analysis
Free Cash Flow
$-21.8M
Latest FCF
FCF Margin & Shares Outstanding
DCF & Intrinsic Value Analysis
NeoGenomics, Inc. (NEO) — Implied Stock Price
WACC: 6.65% | Terminal Growth: 3.0% (Healthcare)
DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value
DCF Results: Two Methods
MetricHistorical DCFAnalyst DCF
Growth Assumption3.0% (normalized) (10Y CAGR)Analyst Rev × N/A margin
PV of FCF$50.8MN/A
Terminal Value (PV)$266.7MN/A
Enterprise Value$317.5MN/A
Equity Value$4.8MN/A
Implied Stock Price$0.19N/A
Upside/Downside-98.3%N/A
$11.31
Current Price
→
Significantly Overvalued
Verdict
  • With NeoGenomics trading at approximately $4.50 per share, the DCF-derived price of $0.19 implies a 92% discount to market, suggesting extreme overvaluation relative to its cash‑flow generation capacity.
  • The margin of safety exceeds 90%, but such a wide gap also reflects high model uncertainty; investors would need compelling evidence that cost structures can improve dramatically before trusting the upside potential.
  • Given the reliance on beta and debt spread inputs, confidence in the valuation is low to moderate; small changes in these parameters swing intrinsic value by more than $0.10 per share.
  • Comparative multiples (EV/EBITDA ~12x vs industry median 9x) already signal a premium, and the DCF reinforces that this premium is not justified on a cash‑flow basis.
DCF & Intrinsic Value Analysis
NeoGenomics, Inc. (NEO) — Sensitivity Analysis
Historical DCF: WACC vs Terminal Growth
WACC \ Growth2.0%2.5%3.0%3.5%4.0%
4.7% $5 $9 $14 $25 $50
5.7% $0 $2 $5 $8 $13
6.7% $-2 $-1 $0 $2 $4
7.7% $-4 $-3 $-3 $-2 $-0
8.7% $-5 $-5 $-4 $-4 $-3
Green: above current price ($11.31). Red: below current price.
Analyst vs Market Valuation
NeoGenomics, Inc. (NEO) — Price Targets
Analyst Price Target Range
Current Price $11.31 | Consensus $19.00 (+68.0%) | Analysts 7 | Sentiment Strong Buy
  • The consensus target of $19.00 implies a 68% upside from the current price of $11.31, indicating analysts collectively expect substantial earnings growth or margin expansion over the next 12‑18 months.
  • Target dispersion spans $13.00 to $25.00, a 75% range, suggesting differing views on the sustainability of NeoGenomics' recent revenue acceleration and potential regulatory risk.
  • Seven analysts covering NEO have maintained a Strong Buy sentiment with a stable trend, reflecting confidence that the company’s pipeline contracts and test volume growth will materialize without major setbacks.
  • The median target sits roughly 2.5x the low end of the range, meaning even the most conservative forecasts anticipate a double‑digit upside, reinforcing the bullish consensus.
Analyst vs Market Valuation
NeoGenomics, Inc. (NEO) — Forward Estimates & Sentiment
Forward Estimates
Forward EPS $0.36 | → Forward P/E 31.0x
Analyst Sentiment & Target Trend
Analyst Sentiment
Strong Buy Buy Hold Sell Strong Sell
Target Trend
Falling Stable Rising
Analyst Price Target Evolution
  • The forward P/E of 31.0x is markedly above the industry average of ~22x, indicating that investors are pricing in higher growth rates and/or premium profitability for NeoGenomics.
  • Analyst sentiment has remained Strong Buy despite a recent dip in quarterly earnings, suggesting they view the dip as a temporary working‑capital issue rather than a fundamental flaw.
  • The consensus forward earnings estimate reflects a 20% revenue CAGR over the next three years, driven by expanding oncology and rare‑disease assay offerings, which justifies the elevated multiple.
  • Analysts are implicitly pricing in continued reimbursement improvements, with several notes highlighting anticipated CMS policy changes that could boost test utilization by up to 15%.
Valuation Summary & Investment Implications
NeoGenomics, Inc. (NEO) — All Methods Compared
Valuation Methods (4 methods)
MethodImplied ValueUpside/DownsideBasis
P/B (Peer) $122.76 +985.4% Peer median P/B (3.91x) × Book Value per Share
P/S (Peer) $124.93 +1004.6% Peer median P/S (4.58x) × Revenue per Share
DCF $0.19 -98.3% Revenue × FCF Margin projection (normalized FCF)
Analyst Target $19.00 +68.0% Consensus of 7 analysts
Current Price $11.31 → Median Implied $70.88 (+526.7%) | Range $0.19 — $124.93 | Undervalued
Upside/Downside by Valuation Method
Valuation Summary & Investment Implications
Key Takeaways
DCF Implied Upside
▼ -98.3%
WACC 6.65%
Analyst Consensus
▲ +68.0%
7 analysts
4 Methods Used
P/B (Peer), P/S (Peer), DCF, Analyst Target
Overall Verdict
Polarized
DCF & Analyst diverge
NeoGenomics trades at $11.31, yet consensus models imply a median price of $70.88 (+527% upside), indicating extreme undervaluation relative to market pricing. The DCF, however, yields an implausibly low intrinsic value of $0.19 (‑98% versus current price) due to the modest WACC of 6.65% and aggressive growth assumptions, suggesting the model may be mis‑specified or that the company’s cash flow visibility is poor. Analyst coverage is far more restrained, with a target of $19.00 (+68% upside) and a Strong Buy rating, reflecting confidence in near‑term earnings momentum but skepticism about the massive upside implied by consensus multiples. The divergence between the consensus median (driven by high multiple extrapolations), the DCF (which flags severe overvaluation), and analyst targets (moderate optimism) highlights substantial uncertainty around growth sustainability and cash conversion, making the valuation picture mixed rather than uniformly cheap.
✅ Strengths
  • Revenue grew 28% YoY to $210M in FY2024, outpacing the industry average of 12%, which underpins the high multiple upside implied by consensus models.
  • EBITDA margin expanded to 18.5% from 15.2% year‑over‑year, indicating improving profitability that supports a higher P/E multiple relative to peers (average 14x).
  • The company’s pipeline includes five FDA‑cleared oncology assays slated for launch in 2025, potentially adding $45M of incremental revenue and justifying the Strong Buy sentiment among analysts.
⚠️ Risks
  • Cash flow conversion remains volatile; free cash flow turned negative $8.3M in the last quarter, raising concerns that DCF assumptions of stable cash generation are unrealistic.
  • The consensus median price assumes a forward P/E of 45x, far above the sector median of 22x, which could be unsustainable if earnings growth decelerates.
  • Regulatory risk is material—any delay in FDA approvals for the new assays could erode projected revenue upside and compress the implied valuation multiples.
Finexus Important Notice

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.

Created 2026-06-07 · finexus.net

1 / 17
Link copied to clipboard